Table 2

Summary of the literature: Frequency of MSI in ovarian cancer. The total number of MSI, the number of MS markers used for the analysis and the number of MSI per histological subtype (if mentioned) is given for each study.

MSI

MS markers

Histology

NCI-CP

total

SE

EN

CC

MU

MM

PD


Helleman et al.

0/75

(0%)

2

2

0/36 (0%)

0/13 (0%)

0/3 (0%)

0/10 (0%)

0/8 (0%)

0/3 (0%)

Mesquita et al.2005

0/34

(0%)

1

2

0/26 (0%)

-

0/8 (0%)

-

-

-

Gifford et al. 2004

2/138

(1%)

3

6

Not mentioned

Catasus et al. 2004

5/54

(9%)

5

5

EN, CC and MM histology

Cai et al.2004

6/42

(14%)

5

5

-

-

6/42 (14%)

-

-

-

Liu et al.2004

15/74

(20%)

4

4

-

15/74 (20%)

-

-

-

-

Singer et al.2004

6/75

(8%)

5

11

5/53 (9%)

1/14 (7%)

0/3 (0%)

0/5 (0%)

-

-

Geisler et al.2003

21/125

(17%)

5

6

10/69 (14%)

6/22 (27%)

0/4 (0%)

2/9 (22%)

-

1/2 (50%)

Watanabe et al. 2001

2/24

(8%)

5

10

Not mentioned

Sood et al. 2001

13/109

(12%)

5

14

Not mentioned

Gras et al.2001

7/76

(9%)

5

10

0/17 (0%)

1/48 (2%)

1/8 (13%)

0/2 (0%)

0/6 (0%)

-

Buller et al. 2001

22/56

(39%)

5

6

Not mentioned

Chiaravalli et al.2001

3/16

(19%)

2

3

0/8 (0%)

1/2 (50%)

-

2/4 (50%)

-

0/2 (0%)

Ohwada et al.2000

15/61

(25%)

1

5

4/32 (13%)

-

-

11/29 (38%)

-

-

Allen et al.2000

1/25

(4%)

2

4

1/16 (6%)

0/2 (0%)

0/2 (0%)

0/1 (0%)

-

0/4 (0%)

Colella et al. 1998

3/20

(15%)

0

3

Not mentioned

Sood et al. 1997

13/78

(17%)

1

9

Not mentioned

Sood et al. 1996

11/68

(16%)

1

9

34 serous and 34 not serous

Tangir et al.1996

2/31

(6%)

0

13

2/31 (6%)

-

-

-

-

-

Arzimanoglou et al. 1996

11/90

(12%)

1

3

Not mentioned

Fujita et al.1995

7/44

(16%)

0

4

2/22 (9%)

5/10 (50%)

0/4 (0%)

0/8 (0%)

-

-


Total

165/1315

(13%)

24/310 (8%)

29/185 (16%)

7/74 (9%)

15/68 (22%)

0/14 (0%)

1/11 (9%)


Abbreviations: SE serous, EN endometrioid, CC clear cell, MU mucinous, MM mixed mullerian, PD poorly differentiated, - not present, MS microsatellite, NCI-CP National Cancer Institute Consensus Panel.

Helleman et al. BMC Cancer 2006 6:201   doi:10.1186/1471-2407-6-201

Open Data